R Squared Ltd Purchases Shares of 2,240 Amedisys, Inc. (NASDAQ:AMED)

R Squared Ltd bought a new stake in shares of Amedisys, Inc. (NASDAQ:AMED) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 2,240 shares of the health services provider’s stock, valued at approximately $203,000.

Other large investors have also bought and sold shares of the company. Pacer Advisors Inc. raised its holdings in shares of Amedisys by 11,621.9% in the 4th quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after acquiring an additional 553,435 shares during the last quarter. KBC Group NV boosted its holdings in Amedisys by 76.8% in the 4th quarter. KBC Group NV now owns 1,158 shares of the health services provider’s stock worth $105,000 after buying an additional 503 shares during the period. Blue Trust Inc. increased its position in shares of Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares during the period. Exchange Traded Concepts LLC raised its position in shares of Amedisys by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,703 shares of the health services provider’s stock worth $699,000 after buying an additional 195 shares in the last quarter. Finally, Impact Partnership Wealth LLC purchased a new position in Amedisys in the 4th quarter worth approximately $226,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Stock Performance

Amedisys stock opened at $92.48 on Wednesday. The stock has a market cap of $3.03 billion, a P/E ratio of 36.70, a price-to-earnings-growth ratio of 1.83 and a beta of 0.72. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The firm’s fifty day moving average price is $89.28 and its 200-day moving average price is $94.08.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, November 6th. The health services provider reported $1.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The firm had revenue of $587.67 million during the quarter, compared to analysts’ expectations of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Amedisys’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.98 earnings per share. On average, equities research analysts expect that Amedisys, Inc. will post 4.43 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.